The research-based biopharmaceutical company called AstraZeneca has submitted a plea in front of the United States to grant them the approval of emergency use authorization for a new antibody therapy founded by them against Covid-19 which they claim is beneficial for the people whose immune systems have become weak and are not able to properly respond to the vaccines.
The Anglo-Swedish drugmaker made a statement on Tuesday in which they stated that a late-stage trial which was conducted with the Food and Drug Administration, showed that the drug helped in reducing the chances of a person from developing any symptoms related to Covid-19 by seventy-seven percent.
U.S. Authorization Of Drug Requested AstraZeneca For Prevention Of Covid
AstraZeneca has also stated that the antibody therapy which is known as AZD7442 has proven quite helpful in providing protection to people whose immune system is not strong enough to respond to the coronavirus vaccines, or who need to get booster jabs for increased protection, such as military personnel.
The AZD7442 antibody therapy is known to be quite effective as for any vaccine to work efficiently, they have to rely on the human immune system for the development of specific antibodies and infection-fighting cells.
But this is not the case with AZD7442, as they are antibodies that are lab-grown and are developed in such a way that they linger or hang around inside the human body for months, and it works by containing any virus that tries to enter the human body.
It would be a major success for AstraZeneca if the United States grants approval to AZD7442. It is a lab-grown antibody that is based on the data discovered on two antibodies discovered by Vanderbilt University Medical Center in the United States.
The vaccine developed by AstraZeneca to fight the coronavirus is still not approved in the United States. AstraZeneca has also stated that there are conversations in the process that concern the supply agreements for the AZD7442 with the United States and other governments.
Rival competitors of AstraZeneca, such as Eli Lilly, GlaxoSmithKline with Vir, Regeneron, et cetera, are in the process of synthesizing therapies of coronavirus that are based on the same level of monoclonal antibodies, to get into the race of competition for the Covid-19 prevention and treatment. Despite this, AstraZeneca has proven to be far ahead of them in this league and cemented its reign.
Although it has maintained itself on the top, the vaccine invented by AstraZeneca to battle the coronavirus, which is called Vaxzevria, is still on the waiting list to be approved in the United States. Also, the majority of the people who want to receive the shots have received the vaccination from other vaccines such as Pfizer-BioNTech, Moderna, and Johnson and Johnson’s Janssen.
The first trial results of the AZD7442 were published in August, which took place three months after the therapy injection. The company is expecting that the vaccination shot can be promoted and publicized for a year since the trial officials are expected to observe the participants under trial for not less than fifteen months.